Remove Cost Control Remove Pharmaceuticals Remove Sourcing
article thumbnail

Beyond the Big Three PBMs: Examining a Potential Trend

Perficient Digital Transformation

This ongoing struggle contributes to the broader atmosphere of tension within the pharmaceutical sector. Patients bear the financial burden of decisions made behind closed doors, emphasizing the need for a more transparent and patient-centered approach in the pharmaceutical ecosystem.

article thumbnail

How To Overcome Three Challenges Facing Biotech Companies In 2021

Velocity Global

In the face of steep internal costs and a lengthy process before generating revenue, it’s no surprise that the vast majority of biotech and life science companies see cost control as a major challenge. In fact, 87% of pharmaceutical companies believe they will have to comply with additional U.S.